GlassScriptPhysician profile
Daniel W O Neill
NPI 1972578508
$5,066.29
in general payments reported to CMS, 2019-2025
37 companies · $926 in 2025
The $926 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,436 · 2020: $784 · 2021: $156 · 2022: $65.77 · 2023: $696 · 2024: $1,002 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584 · Education: $41.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.55 |
| Education | $41.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $756.78 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $685.37 | 2019-2025 | |
| Novo Nordisk INC | $573.47 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $490.91 | 2019-2025 | Farxiga, Breztri, Wainua |
| Glaxosmithkline, LLC. | $297.89 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.02 | 2019-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $218.79 | 2023-2025 | Sunosi, Auvelity |
| Lilly USA, LLC | $184.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $161.54 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $151.15 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $136.61 | 2019-2025 | |
| Astellas Pharma US INC | $114.88 | 2019-2023 | Veozah |
| Allergan, INC. | $103.77 | 2020 | |
| Phathom Pharmaceuticals, INC. | $100.62 | 2024-2025 | Voquezna |
| Amgen INC. | $98.47 | 2022-2024 | Repatha |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel O Neill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.